Goldman Sachs
COCP icon

Goldman Sachs’s Cocrystal Pharma COCP Stock Holding History

Goldman Sachs’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,062
Closed -$5K – 6298
2022
Q2 		$5K Buy
+1,062
New +$5.66K ﹤0.01% 6333
2022
Q1 		– Sell
-1,473
Closed -$11K – 6602
2021
Q4 		$11K Sell
1,473
-11,690
-89% -$120K ﹤0.01% 6408
2021
Q3 		$166K Buy
13,163
+1,649
+14% +$21.8K ﹤0.01% 5783
2021
Q2 		$173K Buy
11,514
+4,411
+62% +$67K ﹤0.01% 5792
2021
Q1 		$118K Buy
7,103
+4,414
+164% +$89.6K ﹤0.01% 5793
2020
Q4 		$44K Sell
2,689
-4,760
-64% -$66.1K ﹤0.01% 5394
2020
Q3 		$83K Buy
+7,449
New +$136K ﹤0.01% 5118
2018
Q3 		– Sell
-3,459
Closed -$152K – 5586
2018
Q2 		$152K Buy
+3,459
New +$128K ﹤0.01% 5089

Other funds holding COCP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's COCP Position: Q3 2022 in Review

Goldman Sachs sold out of Cocrystal Pharma (COCP) in Q3 2022, closing a stake of 1,062 shares — an estimated $5K sold.

Goldman Sachs first reported a position in COCP in Q2 2018 and held it in 8 quarters. The position peaked at $173K in Q2 2021. 27 funds tracked by Wall St. Rank hold COCP as of Q3 2022.

  • Goldman Sachs reported no remaining Cocrystal Pharma position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,062 Cocrystal Pharma shares in Q3 2022, an estimated $5K.
  • Goldman Sachs first reported a position in Cocrystal Pharma in Q2 2018 and held it in 8 quarters.
  • Goldman Sachs's Cocrystal Pharma position peaked at $173K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.